Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2007-03-20
2011-11-01
Szperka, Michael (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S133100, C424S141100, C424S153100, C530S387300, C530S388100, C530S388220, C514S013800
Reexamination Certificate
active
08048421
ABSTRACT:
This invention provides an agonist antibody to a human thrombopoietin receptor (alias: human c-Mpl). More particularly, this invention provides an agonist antibody to a human thrombopoietin receptor, wherein the agonist antibody comprises: antibody constant regions comprising (1) amino acid sequences in a heavy chain constant region and a light chain constant region of a human antibody, (2) an amino acid sequence of a heavy chain constant region with a domain substituted between human antibody subclasses, and an amino acid sequence of a light chain constant region of a human antibody, or (3) amino acid sequences comprising a deletion(s), substitution(s), addition(s), or insertion(s) of one or several amino acid residues in the amino acid sequences of (1) or (2) above; and antibody variable regions capable of binding to and activating a human thrombopoietin receptor; and wherein the agonist antibody has the properties: (a) that the antibody induces colony formation at a concentration of 10,000 ng/ml or lower as determined by the CFU-MK colony formation assay using human umbilical-cord-blood-derived CD34+ cells; and (b) that the antibody has a maximal activity at least 50% higher than that of PEG-rHuMGDF and an 50% effective concentration (EC50) of 100 nM or less in the cell proliferation assay using UT7/TPO cell. Also provided is a pharmaceutical composition for treating thrombocytopenia comprising said antibody.
REFERENCES:
patent: 5693762 (1997-12-01), Queen et al.
patent: 5980893 (1999-11-01), Avraham et al.
patent: 6153190 (2000-11-01), Young et al.
patent: 6342220 (2002-01-01), Adams et al.
patent: 2005/0181450 (2005-08-01), Mikoshiba
patent: 2006/0024275 (2006-02-01), Murray et al.
patent: 2007/0148163 (2007-06-01), Takahashi et al.
patent: 2 327 505 (1999-11-01), None
patent: 1 327 680 (2003-07-01), None
patent: 1 616 881 (2006-01-01), None
patent: 11-507819 (1999-07-01), None
patent: 2002-512776 (2002-05-01), None
patent: 2004-129612 (2004-04-01), None
patent: WO 96/40231 (1996-12-01), None
patent: WO 99/10494 (1999-03-01), None
patent: WO 99/55369 (1999-11-01), None
patent: WO 03/055997 (2003-07-01), None
patent: WO 2004/030615 (2004-04-01), None
patent: WO 2004/041170 (2004-05-01), None
patent: WO 2005/063981 (2005-07-01), None
Janeway et al., Immunobiology, 3rdedition, 1997, Garland Press, pp. 3:1-3:11.
Corti et al., Lymphokine Cytokine Res. 1994, 13:183-90.
Kai et al., Blood, (Nov. 16, 2006) vol. 108, No. 11, Part 1, pp. 336A-337A.
Supplementary European Search Report EP 07 73 9974 Dated Jun. 28, 2010.
Leonard G. Presta, “Engineering Antibodies for Therapy”, Current Pharmaceutical Biotechnology, 2002, 3, 237-256.
Bijia Deng et al., “An Agonist Murine Monoclonal Antibody to the Human c-MPL Receptor Stimulates Megakaryocytopoiesis”, Blood, vol. 92, No. 6, Sep. 15, 1998; pp. 1981-1988.
Najet Debili et al., “The Mpl-Ligand or Thrombopoietin or Megakaryocyte Growth and Differentiative Factor Has Both Direct Proliferative and Differentiative Activities on Human Megakaryocyte Progenitors”, Blood, vol. 86, No. 7, Oct. 1, 1995: pp. 2516-2525.
Kazuhiro Motoki et al., “Preparation of Human Antibody Using KM mouse and it's Clinical Application”, Igaku No Ayumi, vol. 211, No. 7, 2004, pp. 733-734.
Hideomi Yamada et al., “IRBIT wa pNBC1 no Makuhatsugen o Sokushin suru”, The Japanese Journal of Nephrology, 2005, vol. 47, No. 3, p. 288 “P-300”.
Eiten Gross et al., “Structural determinants and significance of regulation of electrogenic Na+—HCO3 cotransporter stoichiometry”, Am. J. Physiol. Renal. Physiol. 283: F879-F887, 2002.
Kyoko Shirakabe et al., “IRBIT, an inositol 1,4,5-trisphosphate receptor-binding protein, specifically binds to and activates pancreas-type Na+/HCO3 contransporter 1 (pNBC1)”, PNAS, vol. 103, No. 25, Jun. 20, 2006, pp. 9542-9547.
Benoit Devogelaere et al., “Binding of IRBIT to the IP3 Receptor: Determinants and Functional Effects”, Biochemical & Biophysical Research Communications 343 (2006) 49-56.
Hideaki Ando et al., “IRBIT, a Novel Inositol 1,4,5-Trisphosphate (IP3) Receptor-binding Protein Is Released from IP3 Receptor upon IP3 Binding to the Receptor”, The Journal of Biological Chemistry, vol. 278, No. 12, Issue of Mar. 21, pp. 10602-10612, 2003.
Son et al., J. Immunological Methods 286: 187-201 (2004)—Abstract.
Masayuki Kai et al., “Switching constant domains enhances agonist activities of antibodies to a thrombopoietin receptor,” Nature Biotechnology 26: 209-11 (2008).
Hagiwara Tetsuya
Kai Masayuki
Kataoka Shiro
Motoki Kazuhiro
Yoshida Hideaki
Bent Stephen A.
Foley & Lardner LLP
Kyowa Hakko Kirin Co., Ltd.
Szperka Michael
LandOfFree
Agonist antibody to human thrombopoietin receptor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Agonist antibody to human thrombopoietin receptor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Agonist antibody to human thrombopoietin receptor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4295156